Product
AI AGENTS
AI APPLICATIONS
OTHERS
Solutions
INDUSTRIES
USE CASES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
PatSnap Eureka Platform
Agents for IP
Agents for Engineering
Agents for Life Sciences
Agents for Materials
PatSnap Eureka Desktop
NEWAnalytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisOpen Platform
NEWProfessional Services
Customer Stories
Newsroom
Blog
Global Innovation Report
Glossary
Webinars & Training
Frontier
User Community
R&D Benchmark Calculator
Trust and Security
PatentBench
NEWLLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report Explore the 2026 lung organoid drug screening landscape: key technology clusters, patent leaders, geographic trends, and emerging AI-driven platforms for precision oncology.
Article | Report AXS-07, Axsome's meloxicam/rizatriptan FDC, received an FDA CRL for CMC issues — not efficacy. How does it stack up against rimegepant and ubrogepant?
Article | Report No patent or literature data was available to support this article. Learn why evidence-based analysis requires sourced records and how to resubmit.
Article | Report How AI is reshaping weather forecasting in 2026: patent landscape, key technology clusters, top assignees, and emerging commercial directions mapped from patent and literature data.
Article | Report Amycretin's unimolecular GLP-1/amylin co-agonist design vs CagriSema's 22.7% phase 3 weight loss. Novo Nordisk's dual obesity pipeline strategy decoded.
Article | Report How do Bayesian optimization and genetic algorithms differ for experimental design in materials discovery? A practical guide for R&D teams navigating high-dimensional search spaces.
Article | Report Explore the 2026 pressure-sensitive adhesive materials landscape for electronics and medical devices: key chemistries, application domains, regulatory drivers, and IP trends.
Article | Report Cytosine base editor (CBE) patent and technology landscape 2026: key assignees, delivery strategies, deaminase engineering, and emerging clinical directions.
Article | Report Key technical considerations for designing high-voltage solid-state circuit breakers (SSCBs) for DC microgrid protection — topologies, semiconductors, and fault strategies.
Article | Report GDF15 analogues and the GFRAL receptor pathway are reshaping obesity drug development. Explore WVE-007, Wave Life Sciences, and the IP landscape for this novel mechanism.
Article | Report Efruxifermin's Phase 2b BALANCED trial showed 41% fibrosis improvement in MASH cirrhosis. Explore Akero's FGF21 IP estate and Roche's post-acquisition strategy.
Article | Report Map the 2026 single cell epigenomics landscape: scATAC-seq, CUT&Tag, spatial epigenomics, multi-modal profiling, and AI-driven bioinformatics for clinical translation.
Article | Report Explore how Design for Reliability and Design for Testability differ in aerospace avionics — from FMEA and fault tolerance to built-in test and DO-254 compliance.
Article | Report Mapping the 2026 AV occupancy prediction patent landscape: OGMs, trajectory forecasting, planning-integrated prediction, and who's filing where across 70+ records.
Article | Report A research guide to bio-based epoxy resin materials for composites and coatings in 2026: key technology classes, search strategies, and IP intelligence sources.